GILDESS FE 1.5/30
Clinical safety rating
cautionComprehensive clinical and safety monograph for GILDESS FE 1.5/30 (GILDESS FE 1.5/30).
Combination oral contraceptive: ethinyl estradiol (estrogen) and levonorgestrel (progestin) suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
| Metabolism | Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes conjugation (glucuronidation and sulfation). Levonorgestrel: metabolized by reduction and conjugation; CYP3A4 involved. |
| Excretion | Ethinyl estradiol (EE) is primarily excreted in urine (40-45%) and feces (40-45%) as glucuronide and sulfate conjugates; less than 8% is excreted unchanged. Gestodene is extensively metabolized; its metabolites are excreted in urine (50-60%) and feces (30-40%), with less than 1% unchanged. |
| Half-life | Ethinyl estradiol: terminal elimination half-life approximately 13-27 hours (mean ~17 hours); clinical context: supports daily dosing with steady state achieved in ~1 week. Gestodene: terminal elimination half-life approximately 12-15 hours; clinical context: allows for maintaining stable serum concentrations with once-daily dosing. |
| Protein binding | Ethinyl estradiol: 97-98% bound to albumin; gestodene: 65-75% bound to sex hormone-binding globulin (SHBG) and 25-35% bound to albumin; total binding ~99%. |
| Volume of Distribution | Ethinyl estradiol: apparent Vd ~2.5-4.0 L/kg (mean ~3 L/kg); indicates extensive tissue distribution beyond plasma volume. Gestodene: apparent Vd ~0.7-1.0 L/kg; suggests moderate distribution to tissues. |
| Bioavailability | Ethinyl estradiol: oral bioavailability approximately 40-45% due to first-pass metabolism (sulfation and glucuronidation in gut wall and liver); interindividual variability significant. Gestodene: oral bioavailability nearly 100% (99-100%) due to minimal first-pass metabolism; high and consistent absorption. |
| Onset of Action | Oral administration: contraceptive effect (ovulation inhibition) occurs after 7 days of consistent dosing when initiated on day 1 of menstrual cycle; if started later, backup contraception needed for 7 days. |
| Duration of Action | Contraceptive effect persists for 24 hours with daily dosing; after discontinuing, ovulation returns within 1-2 weeks in most women, though some may experience delay. |
| Molecular Weight | 312.4 |
| Action Class | Oral Contraceptive; Estrogen-Progestin Combination |
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73 m²) due to potential estrogen-related fluid retention and hypertension. |
| Liver impairment | Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; closely monitor liver function. |
| Pediatric use | Not indicated for use before menarche. Post-menarche: same as adult dosing; one tablet orally once daily. |
| Geriatric use | Not indicated for use in postmenopausal women due to lack of efficacy for contraception and potential increased thromboembolic risk. |
| 1st trimester | Use not recommended; multiple studies show increased risk of cardiovascular malformations with combined hormonal contraceptives (CHCs) in early pregnancy. |
| 2nd trimester | Contraindicated in pregnancy; not indicated during second trimester due to continued potential risks. |
| 3rd trimester | Contraindicated in pregnancy; not indicated during third trimester. |
Clinical note
Comprehensive clinical and safety monograph for GILDESS FE 1.5/30 (GILDESS FE 1.5/30).
| Placental transfer | Both ethinyl estradiol (MW 296.4 Da) and levonorgestrel (MW 312.4 Da) cross the placenta; placental transfer ratio is approximately 0.8–1.0 for levonorgestrel and varies for ethinyl estradiol. |
| Breastfeeding | Small amounts of ethinyl estradiol and levonorgestrel pass into breast milk; may reduce milk production and quality. Not recommended during lactation, especially in the first 6 months postpartum. Use alternative contraception. |
| Lactation Rating | L5 (Avoid) per LactMed; contraindicated per manufacturer. |
| Teratogenic Risk | Pregnancy category X. Use contraindicated in pregnancy due to estrogenic effects on fetal development. First trimester: increased risk of congenital anomalies (cardiovascular, limb defects). Second and third trimesters: potential for fetal harm, including jaundice and liver dysfunction. |
| Fetal Monitoring | Pregnancy test prior to initiation. Monitor for symptoms of thromboembolism, hypertension, liver dysfunction. No routine fetal monitoring required if contraindication observed. |
| Fertility Effects | Reversible suppression of ovulation. No long-term impact on fertility after discontinuation. May cause transient menstrual irregularities post-use. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially >35 years) and number of cigarettes smoked. Women >35 years who smoke should not use this product.
| Common Effects | Nausea, Headache, Breast tenderness, Weight changes, Irregular uterine bleeding, Mood changes, Acne |
| Serious Effects | Venous thromboembolism (VTE), Arterial thromboembolism (e.g., stroke, myocardial infarction), Hepatic adenoma or hepatocellular carcinoma, Hypertension, Gallbladder disease, Thrombotic thrombocytopenic purpura (TTP), Hemolytic uremic syndrome (HUS) |
PregnancyBreastfeeding (relative contraindication, but generally avoid)History of or current thromboembolic disorders (e.g., DVT, PE)Cerebrovascular disease (e.g., stroke, TIA)Coronary artery disease (e.g., MI, angina)Valvular heart disease with complicationsSevere hypertension (systolic ≥160 mmHg or diastolic ≥100 mmHg)Diabetes mellitus with vascular involvement (retinopathy, nephropathy, neuropathy)Headaches with focal neurological symptoms (e.g., migraine with aura, especially if >age 35)Breast cancer (current or history)Estrogen-dependent neoplasia (e.g., endometrial cancer)Undiagnosed abnormal uterine bleedingCholestatic jaundice of pregnancy or jaundice with prior OCP useLiver tumors (benign or malignant), acute hepatitis, severe cirrhosisKnown hypersensitivity to any componentSmoking >15 cigarettes/day in women ≥35 years
| Precautions | Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction), Carcinoma of the breast and reproductive organs, Hepatic neoplasia, Gallbladder disease, Carbohydrate and lipid metabolism effects, Elevated blood pressure, Headache, Bleeding irregularities, Ocular lesions (e.g., retinal thrombosis), Depression |
| Food/Dietary | No significant food interactions. Grapefruit juice may slightly increase ethinyl estradiol levels but not clinically relevant. The iron component may cause gastrointestinal discomfort; taking with food can reduce this, but avoid taking with dairy (calcium) or caffeine as they may reduce iron absorption. Iron tablets should be taken with water or vitamin C source to enhance absorption, but not with tea, coffee, or milk. |
| Clinical Pearls | GILDESS FE 1.5/30 is a combination oral contraceptive containing ethinyl estradiol 30 mcg and gestodene 1.5 mg. Gestodene is a third-generation progestin with high progestational activity and minimal androgenic effects. The iron component (ferrous fumarate) is included to counteract menstrual blood loss. This formulation is associated with a lower risk of venous thromboembolism compared to second-generation pills but still carries a risk, particularly in smokers over 35. It should be taken at the same time daily to maintain efficacy. Breakthrough bleeding is common in the first few cycles; if persistent, rule out other causes. The iron tablets are not for contraceptive use and should be taken daily during the placebo week. |
| Patient Advice | Take one tablet daily at the same time, preferably after an evening meal to minimize nausea. · If you miss a dose, follow the package instructions: if missed by less than 12 hours, take it immediately; if more than 12 hours, take the last missed pill and use backup contraception for 7 days. · Use additional barrier contraception for the first 7 days of starting the pill, or if starting after day 5 of cycle, for the first cycle. · Smoking increases the risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication. · Seek immediate medical attention if you experience symptoms of a blood clot: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache. · The iron tablets are not for contraception; they help replace iron lost during menstruation. · Do not use this medication if you are pregnant, have a history of blood clots, certain migraines, liver disease, or hormone-sensitive cancer. · Antibiotics (except rifampin) generally do not affect efficacy, but always consult your doctor if you are prescribed any new medication. |
Loading safety data…